Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers.
about
Endothelin receptor antagonists for pulmonary arterial hypertensionGuanylate cyclase stimulators for pulmonary hypertensionTreatment of patients with chronic thrombo embolic pulmonary hypertension: focus on riociguatThe limits of oral therapy in pulmonary arterial hypertension managementHeme-dependent and independent soluble guanylate cyclase activators and vasodilation.Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary diseaseAbsorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.Leads for the treatment of pulmonary hypertension.Riociguat for pulmonary hypertension.Riociguat for the treatment of pulmonary hypertension.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Stimulators of soluble guanylyl cyclase: future clinical indicationsRiociguat: first global approval.Riociguat for pulmonary hypertension.Riociguat for the treatment of pulmonary hypertension.Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.Riociguat: a novel new drug for treatment of pulmonary hypertension.New pharmacotherapy options for pulmonary arterial hypertension.Riociguat for the treatment of pulmonary hypertension.Riociguat for the treatment of pulmonary hypertension: a safety evaluation.Contemporary Approaches to Modulating the Nitric Oxide-cGMP Pathway in Cardiovascular Disease.Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorptionRiociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolamThe sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
P2860
Q24200714-6D03E09D-0792-4619-B6CA-999FDBDB42CBQ26470534-A68AA9D7-CB27-4BFF-B8B1-5F64835553DCQ26746202-BA3F35A2-6029-4F54-B733-D259EF26C367Q26773209-4551B3E3-F497-4CCC-808E-48A61641D151Q27692662-A354B2A3-1F61-4D33-B5D7-193F5C323D5DQ33447738-BDDDF704-9119-4591-9705-3BA909790FE7Q33532813-CC9D24E2-A65D-429F-B71A-6B39AF8DD498Q33596457-D6AD5D92-C9D0-4D04-AA8C-EBB460C22C75Q34179857-87391782-92F9-4F76-B062-276A16F13CAEQ34444990-F33F8CC9-24E8-4157-8279-F3C3F3D23CF8Q35010064-B7F6F3AF-58E5-40B2-AE70-2EBFC4921C3AQ35075847-33B6A0D3-820B-442C-9077-4F16C324FB7BQ35665739-FB23C8EB-E338-427D-8CBB-C8C2EABC9C83Q36734217-01F7A329-1045-479D-B449-8523F3A8FBCFQ36881692-B879ED63-2C65-4B54-8EA0-05D41F745CC9Q36881704-EBFA52A8-55C2-4F1B-A202-A88A3627323DQ36881715-103291A4-0324-4ECF-AFE3-56C5441A7A8CQ36881722-346659A4-8D7E-49ED-9CFE-BAF0C88BB119Q36881733-EC1D4879-939C-475A-8C7C-5785EF067D0FQ37481343-B4E6AD9A-EF29-4089-B7ED-D22F4CDA3717Q37709398-2404B289-ABE6-4AB7-B03E-0B6D75C58876Q37851516-8F99D5EB-84DC-4314-9AE1-D730CDD14216Q38000562-D80E0620-16CD-4E25-B9FA-E54FC94A22C7Q38093420-867051D0-33E0-4C29-9F76-7CEF44555FE0Q38161841-F2A5AE70-DC9E-4823-9E50-CAD287C419FCQ38192059-FE7AA670-FF83-42D9-B979-E4BE7DAE36CAQ38254736-6FC95874-15D8-43D4-8C0A-0966F706FFA9Q38263468-0FC0193D-7B03-444B-9108-91D5E7045B47Q38386942-5881C7A7-1D9F-4591-AD57-6612F1A44D08Q38502798-FE8E1DCF-F16C-400B-B3DB-E1A015EEDDB6Q38569940-3DA8B837-4628-4357-9D5E-D06628BC7E19Q38645382-AED12976-1DA9-4760-81CE-3A7DC79299A9Q38983098-11683DFF-CA41-4A89-A593-F06A3B917B97Q39209626-6803F0D9-4274-4744-A660-35911904C170Q40386143-E89B0854-71C8-41EB-88A7-49325B11CCBBQ41165804-A58E8924-95BA-42D2-9533-A1A110596C75Q41166010-53848313-3DA9-4CE3-8E5F-6CDC08319E45Q41166308-A329A5C0-0BB5-4D21-83D5-C9C89F29097BQ43119916-2EFECF91-1295-4CBC-AAAC-50CED221BBA9Q45811750-CDB7043D-CE13-41F2-9DE1-39DA95995ECA
P2860
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Single-dose pharmacokinetics, ...... dy in healthy male volunteers.
@en
Single-dose pharmacokinetics, ...... dy in healthy male volunteers.
@nl
type
label
Single-dose pharmacokinetics, ...... dy in healthy male volunteers.
@en
Single-dose pharmacokinetics, ...... dy in healthy male volunteers.
@nl
prefLabel
Single-dose pharmacokinetics, ...... dy in healthy male volunteers.
@en
Single-dose pharmacokinetics, ...... dy in healthy male volunteers.
@nl
P2093
P2860
P356
P1476
Single-dose pharmacokinetics, ...... dy in healthy male volunteers.
@en
P2093
Georg Wensing
Gerrit Weimann
Reiner Frey
Sigrun Unger
Ulrike Artmeier-Brandt
Wolfgang Mück
P2860
P304
P356
10.1177/0091270008319793
P577
2008-06-02T00:00:00Z